Abbott Laboratories posted its largest-ever quarter for rapid diagnostics, according to a news release from data analytics and consulting firm GlobalData. The company’s rapid diagnostics segment sold ...

While COVID-19 case counts are currently on the decline in the U.S., the Department of Defense (DOD) thinks we can’t be too prepared. To secure more rapid diagnostic kits, the U.S. Army has inked a $1 ...

Abbott Laboratories plans to reboot production of its rapid COVID-19 tests at a leased facility in Gurnee, just a few months after closing the operation. "As demand for COVID-19 testing has increased, ...

After weathering a nearly billion-dollar dip in rapid COVID testing revenues earlier this year, Abbott’s BinaxNow antigen test sales rebounded following the COVID-19 resurgence due to the delta ...

Abbott's rapid antigen tests are in high demand by consumers and government purchasers. Sales of coronavirus diagnostics tend to spike and crater along with waves of the pandemic. Though the tests ...

INDIANAPOLIS, (WISH) – The holidays are about spreading joy, but it’s also a time when celebrating with friends and family can get us sick. On Tuesday, Dr. Mary Rodgers, a Ph.D. who is an Abbott ...

As people across the country continue to grab at-home, COVID-19 tests off store shelves, Abbott Laboratories — the maker of one of the most popular of those tests — reported a stellar fourth quarter ...

Narrow-moat Abbott ABT posted solid third-quarter results with underlying strength in its device business along with robust recovery in nutrition, which partially offset the ongoing unwinding of its ...

Feb 1 (Reuters) - Abbott Laboratories said it would buy Alere Inc for $5.8 billion and become the leader in point-of-care diagnostic testing, a market that is growing as physicians increasingly adopt ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has petitioned the Internal Revenue ...

We’re not surprised by narrow-moat Abbott’s ABT recalibration of its outlook for COVID-19 testing now that the pandemic has been receding in developed markets. After fine-tuning our already more ...